Nektar Therapeutics | NKTR - Sales Revenues


Nektar Therapeutics reported $21.81M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Baxter International USD 2.7B 270M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 65.41B 9.77B Mar/2026
Dr.Reddys Laboratories INR 75.46B 11.81B Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Xencor USD 4.51M 23.73M Mar/2026